Conversion of the sodium channel activator aconitine into a potent alpha 7-selective nicotinic ligand

D J Hardick, Gary Cooper, T Scott-Ward, I S Blagbrough, Barry V.L. Potter, S Wonnacott

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Methyllycaconitine (MLA) is a competitive antagonist of nicotinic acetylcholine receptors, with a remarkable preference for neuronal [125I]alpha Bgt binding sites. We have begun to investigate the structural basis of its potency and subtype selectivity. MLA is a substituted norditerpenoid alkaloid linked to a 2-(methylsuccinimido)benzoyl moiety. Hydrolysis of the ester bond in MLA to produce lycoctonine diminished affinity for rat brain [125I]alpha Bgt binding sites 2500-fold and abolished affinity for [3H]nicotine and muscle [125I]alpha Bgt binding sites. The voltage-gated Na+ channel activator aconitine, also a norditerpenoid alkaloid, but with significant structural differences from lycoctonine, displayed comparable weak or absent nicotinic activity. Addition of a 2-(methylsuccinimido)benzoyl sidechain to O-demethylated aconitine, to mimic MLA, abolished Na+ channel activation and conferred nanomolar affinity for brain [125I]alpha Bgt binding sites, comparable to that of MLA. We propose that the ester-linked 2-(methylsuccinimido)benzoyl group is necessary for nicotinic potency, but alpha 7 selectivity resides in the norditerpenoid core of the molecule.
Original languageEnglish
Pages (from-to)79-82
Number of pages4
JournalFEBS Letters
Volume365
Issue number1
DOIs
Publication statusPublished - 22 May 1995

Fingerprint

Sodium Channel Agonists
Aconitine
Diterpenes
Ligands
Binding Sites
Alkaloids
Brain
Esters
Nicotinic Receptors
Nicotine
Muscle
Rats
Hydrolysis
Chemical activation
methyllycaconitine
Muscles
Molecules
Electric potential

Keywords

  • Aconitine
  • Animals
  • Binding Sites
  • Binding, Competitive
  • Brain
  • Bungarotoxins
  • Dopamine
  • Dose-Response Relationship, Drug
  • Ligands
  • Membranes
  • Rats
  • Receptors, Nicotinic
  • Sodium Channel Blockers
  • Structure-Activity Relationship
  • Tetrodotoxin
  • Veratridine

Cite this

Hardick, D. J., Cooper, G., Scott-Ward, T., Blagbrough, I. S., Potter, B. V. L., & Wonnacott, S. (1995). Conversion of the sodium channel activator aconitine into a potent alpha 7-selective nicotinic ligand. FEBS Letters, 365(1), 79-82. https://doi.org/10.1016/0014-5793(95)00426-A

Conversion of the sodium channel activator aconitine into a potent alpha 7-selective nicotinic ligand. / Hardick, D J; Cooper, Gary; Scott-Ward, T; Blagbrough, I S; Potter, Barry V.L.; Wonnacott, S.

In: FEBS Letters, Vol. 365, No. 1, 22.05.1995, p. 79-82.

Research output: Contribution to journalArticle

Hardick, DJ, Cooper, G, Scott-Ward, T, Blagbrough, IS, Potter, BVL & Wonnacott, S 1995, 'Conversion of the sodium channel activator aconitine into a potent alpha 7-selective nicotinic ligand', FEBS Letters, vol. 365, no. 1, pp. 79-82. https://doi.org/10.1016/0014-5793(95)00426-A
Hardick DJ, Cooper G, Scott-Ward T, Blagbrough IS, Potter BVL, Wonnacott S. Conversion of the sodium channel activator aconitine into a potent alpha 7-selective nicotinic ligand. FEBS Letters. 1995 May 22;365(1):79-82. https://doi.org/10.1016/0014-5793(95)00426-A
Hardick, D J ; Cooper, Gary ; Scott-Ward, T ; Blagbrough, I S ; Potter, Barry V.L. ; Wonnacott, S. / Conversion of the sodium channel activator aconitine into a potent alpha 7-selective nicotinic ligand. In: FEBS Letters. 1995 ; Vol. 365, No. 1. pp. 79-82.
@article{c8b241d0a75d4578b1478dbc5f658bbf,
title = "Conversion of the sodium channel activator aconitine into a potent alpha 7-selective nicotinic ligand",
abstract = "Methyllycaconitine (MLA) is a competitive antagonist of nicotinic acetylcholine receptors, with a remarkable preference for neuronal [125I]alpha Bgt binding sites. We have begun to investigate the structural basis of its potency and subtype selectivity. MLA is a substituted norditerpenoid alkaloid linked to a 2-(methylsuccinimido)benzoyl moiety. Hydrolysis of the ester bond in MLA to produce lycoctonine diminished affinity for rat brain [125I]alpha Bgt binding sites 2500-fold and abolished affinity for [3H]nicotine and muscle [125I]alpha Bgt binding sites. The voltage-gated Na+ channel activator aconitine, also a norditerpenoid alkaloid, but with significant structural differences from lycoctonine, displayed comparable weak or absent nicotinic activity. Addition of a 2-(methylsuccinimido)benzoyl sidechain to O-demethylated aconitine, to mimic MLA, abolished Na+ channel activation and conferred nanomolar affinity for brain [125I]alpha Bgt binding sites, comparable to that of MLA. We propose that the ester-linked 2-(methylsuccinimido)benzoyl group is necessary for nicotinic potency, but alpha 7 selectivity resides in the norditerpenoid core of the molecule.",
keywords = "Aconitine, Animals, Binding Sites, Binding, Competitive, Brain, Bungarotoxins, Dopamine, Dose-Response Relationship, Drug, Ligands, Membranes, Rats, Receptors, Nicotinic, Sodium Channel Blockers, Structure-Activity Relationship, Tetrodotoxin, Veratridine",
author = "Hardick, {D J} and Gary Cooper and T Scott-Ward and Blagbrough, {I S} and Potter, {Barry V.L.} and S Wonnacott",
year = "1995",
month = "5",
day = "22",
doi = "10.1016/0014-5793(95)00426-A",
language = "English",
volume = "365",
pages = "79--82",
journal = "FEBS Letters",
issn = "0014-5793",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Conversion of the sodium channel activator aconitine into a potent alpha 7-selective nicotinic ligand

AU - Hardick, D J

AU - Cooper, Gary

AU - Scott-Ward, T

AU - Blagbrough, I S

AU - Potter, Barry V.L.

AU - Wonnacott, S

PY - 1995/5/22

Y1 - 1995/5/22

N2 - Methyllycaconitine (MLA) is a competitive antagonist of nicotinic acetylcholine receptors, with a remarkable preference for neuronal [125I]alpha Bgt binding sites. We have begun to investigate the structural basis of its potency and subtype selectivity. MLA is a substituted norditerpenoid alkaloid linked to a 2-(methylsuccinimido)benzoyl moiety. Hydrolysis of the ester bond in MLA to produce lycoctonine diminished affinity for rat brain [125I]alpha Bgt binding sites 2500-fold and abolished affinity for [3H]nicotine and muscle [125I]alpha Bgt binding sites. The voltage-gated Na+ channel activator aconitine, also a norditerpenoid alkaloid, but with significant structural differences from lycoctonine, displayed comparable weak or absent nicotinic activity. Addition of a 2-(methylsuccinimido)benzoyl sidechain to O-demethylated aconitine, to mimic MLA, abolished Na+ channel activation and conferred nanomolar affinity for brain [125I]alpha Bgt binding sites, comparable to that of MLA. We propose that the ester-linked 2-(methylsuccinimido)benzoyl group is necessary for nicotinic potency, but alpha 7 selectivity resides in the norditerpenoid core of the molecule.

AB - Methyllycaconitine (MLA) is a competitive antagonist of nicotinic acetylcholine receptors, with a remarkable preference for neuronal [125I]alpha Bgt binding sites. We have begun to investigate the structural basis of its potency and subtype selectivity. MLA is a substituted norditerpenoid alkaloid linked to a 2-(methylsuccinimido)benzoyl moiety. Hydrolysis of the ester bond in MLA to produce lycoctonine diminished affinity for rat brain [125I]alpha Bgt binding sites 2500-fold and abolished affinity for [3H]nicotine and muscle [125I]alpha Bgt binding sites. The voltage-gated Na+ channel activator aconitine, also a norditerpenoid alkaloid, but with significant structural differences from lycoctonine, displayed comparable weak or absent nicotinic activity. Addition of a 2-(methylsuccinimido)benzoyl sidechain to O-demethylated aconitine, to mimic MLA, abolished Na+ channel activation and conferred nanomolar affinity for brain [125I]alpha Bgt binding sites, comparable to that of MLA. We propose that the ester-linked 2-(methylsuccinimido)benzoyl group is necessary for nicotinic potency, but alpha 7 selectivity resides in the norditerpenoid core of the molecule.

KW - Aconitine

KW - Animals

KW - Binding Sites

KW - Binding, Competitive

KW - Brain

KW - Bungarotoxins

KW - Dopamine

KW - Dose-Response Relationship, Drug

KW - Ligands

KW - Membranes

KW - Rats

KW - Receptors, Nicotinic

KW - Sodium Channel Blockers

KW - Structure-Activity Relationship

KW - Tetrodotoxin

KW - Veratridine

U2 - 10.1016/0014-5793(95)00426-A

DO - 10.1016/0014-5793(95)00426-A

M3 - Article

VL - 365

SP - 79

EP - 82

JO - FEBS Letters

JF - FEBS Letters

SN - 0014-5793

IS - 1

ER -